Description - SUMMARY: Implements the Health Care Compliance (HCC) program locally under supervision of the HCC Officer of J&J Vision, specifically related to Due Diligence of Third Party Intermediaries (TPIs). Serves as a partner to business
Position Purpose Maximize urothelial cancer business managing in-line prostate cancer product and developing bladder cancer portfolio(New products) Develop synergistic strategy of PC and BC to deliver holistic approach Deliver the agreed forecast budget and business plan
This role is responsible for 1. As Marketing Supervisor General (MSG), ensuring quality and safety of the companys marketed products in compliance with local regulations applied to MAHs in collaboration with Quality Assurance Manager (Hinseki) and
Position Purpose Develop and implement the business strategy for the HEM product portfolio, with both short-term and long-term business objectives. Oversee and lead all marketing and sales plans to achieve the business objectives within policies and
Position Purpose Develop and implement a business strategy for Janssen Japans introduction into the highly competitive Lung Cancer market with both short term and long-term business objectives Oversee and lead all marketing and sales plans to
Leads and implements the Health Care Compliance (HCC) program locally under supervision of the HCC Officer of MedTech Japan to ensure business practices and activities follow related J&J internal guidelines, local laws and regulations and anti-corruption
Position Purpose The role is closely embedded with the therapeutic area focused business units supporting the development and implementation of robust communication and public affairs strategies that drive the business objectives of the Janssen business and
Leads and implements the Health Care Compliance (HCC) program locally under supervision of the HCC Officer of MedTech Japan to ensure business practices and activities follow related J&J internal guidelines, local laws and regulations and anti-corruption
After 10 years of continuous growth, Janssen Japan (JPKK) business is faced with two years of solid growth in 2024 and 2025. This is an important period to ensure successful delivery of our performance goals. As
